

PHARMANUTRA S.P.A.: NEW LICENCE GRANTED IN THE U.S.A.

The US Patent Office has granted the company a patent for use of Cetylated Fatty Acids (CFA), the basic functional ingredient in the Cetilar® product line.

Pisa, 17 January 2022 – [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), a company specialising in mineral- and iron-based nutritional supplements and medical devices for muscles and joints, has been granted a patent in the United States for use of Cetylated Fatty Acids (CFA).

The patent, granted with number "US 11,186,536", further consolidates PharmaNutra's intellectual property rights for the use of Cetylated Fatty Acids (CFA), the functional ingredient contained in the Cetilar®-branded formulations for the treatment and prevention of muscular and articular problems. Specifically, the new patent safeguards a series of specific stages in the production process. Above all, it envisages both topical and oral use of CFA-based formulations.

Thanks to the development of patents based on complexes of highly concentrated cetylated fatty acids, in recent years PharmaNutra S.p.A. has become one of the top emerging players on the market for medical devices for the rehabilitation of muscle and joint capacity. The granting of the new patent is further consolidation of the patented technologies of the PharmaNutra group, which in 2020, in the USA, was granted, in order: (i) a process patent for CFA production; (ii) registration of the Cetilar® brand; (iii) GRAS designation for its CFA-based oral formulations.

"Another important step in our conquest of the American market. This is a long and complicated journey which, on completion, will open up new scenarios and ample growth prospects for PharmaNutra and our Cetilar® brand, in particular in a country with huge potential," **said Andrea Lacorte, Chairman and co-founder of the PharmaNutra Group.**

PharmaNutra S.p.A.

Founded and led by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra, established in 2003, develops unique nutraceuticals and innovative medical devices, overseeing the entire production process from the proprietary raw materials to the finished product. PharmaNutra is the leading producer, with the SiderAL® trademark, of iron-based nutritional supplements, a field where it holds important patents on Sucrosomial® Technology, and is regarded as one of the top emerging players in medical devices for the rehabilitation of joint capacity thanks to the Cetilar brand. The effectiveness of its products has been demonstrated by extensive scientific evidence, including more than 120 published papers. In Italy, sales are conducted through a network of more than 160 medical representatives, who also handle exclusive marketing of PharmaNutra products to pharmacies and parapharmacies all over the country. International sales in more than 50 countries are managed through 37 partners selected from top pharmaceutical companies. Over the years, the Group has developed a specific intellectual property production and management strategy, based on integrated management of all components: proprietary raw materials, patents, trademarks and clinical data.

PharmaNutra.it

For further information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

investorrelation@PharmaNutra.it

Internal Press Office

press@calabughi.com

Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

mrusso@sprianocommunication.com

Cristina Tronconi

ctronconi@sprianocommunication.com